

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 安 卓 健 有 限 公 司

TIAN AN MEDICARE LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

**SUPPLEMENTAL ANNOUNCEMENT TO
THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
AND
THE INTERIM REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2025**

References are made to the annual report (the “**Annual Report**”) of Tian An Medicare Limited (the “**Company**”) for the year ended 31 December 2024 and the interim report (the “**Interim Report**”) of the Company for the six months ended 30 June 2025, which were published by the Company on 10 April 2025 and 11 September 2025 respectively. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as defined in the Annual Report and the Interim Report.

In addition to the information provided in the Annual Report and Interim Report, the Company would like to provide further information to the paragraph headed “42. SHARE OPTION SCHEME” in the section headed “Notes to the Consolidated Financial Statements in the Annual Report and “22. SHARE OPTION SCHEME” in the section headed “Notes to the Condensed Consolidated Financial Statements” in the Interim Report:

The number of options available for grant under the Scheme mandate is 72,400,363 as at 1 January 2024, 31 December 2024, 1 January 2025 and 30 June 2025 respectively.

The total number of shares available for issue under the Scheme is 72,400,363, representing (i) approximately 6.7% of the total number of issued shares (excluding treasury shares) (i.e. 1,084,815,457) as at the date of the Annual Report (i.e. 10 March 2025) and (ii) approximately 6.7% of the total number of issued shares (excluding treasury shares) (i.e. 1,082,850,457) as at the date of the Interim Report (i.e. 1 August 2025).

The above information is supplemental to the Annual Report and Interim Report and does not affect other information in the Annual Report and Interim Report. Save as disclosed in this announcement, the contents of the Annual Report and Interim Report remain unchanged.

On behalf of the Board
Tian An Medicare Limited
Kong Muk Yin
Executive Director

Hong Kong, 17 September 2025

As at the date of this announcement, the Board comprises Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying being Executive Directors; Mr. Lee Seng Hui (Chairman), Mr. Mark Wong Tai Chun, Mr. Gao Zhaoyuan and Ms. Zhang Yuanyuan being Non-Executive Directors; and Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert, Ms. Yang Lai Sum, Lisa and Mr. Cao Dan being Independent Non-Executive Directors.